

## anti-inflammatoxy and immuno-therapy - all results

| Treatment                   | Number of studies       | clinical deterioration                                                     | clinical improvement                                                              | deaths                                                    | viral clearance                                           |
|-----------------------------|-------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Immunostimulants drugs      | 21 studies <sup>1</sup> | 0.24 [0.10 ; 0.56], 1 RCT, I2=0%<br>certainty unassessable                 | -                                                                                 | 0.39 [0.14 ; 1.08], 9 RCTs, I2=22%<br>inconclusive result | 1.08 [0.45 ; 2.60], 2 RCTs, I2=72%<br>inconclusive result |
| anti-inflammatory therapies | 2 studies <sup>2</sup>  | -                                                                          | -                                                                                 | 0.55 [0.19 ; 1.54], 2 RCTs, I2=0%<br>inconclusive result  | -                                                         |
| corticosteroids             | 2 studies <sup>3</sup>  | -                                                                          | -                                                                                 | 0.98 [0.06 ; 15.76], 2 RCTs, I2=0%<br>inconclusive result | -                                                         |
| inhaled corticosteroids     | 2 studies <sup>4</sup>  | 0.16 [0.03 ; 0.74], 1 RCT, I2=0%<br>demonstrated certainty<br>unassessable | 1.21 [1.08 ; 1.36], 2 RCTs, I2=0%<br>demonstrated moderate degree of<br>certainty | -                                                         | -                                                         |

## Notes

<sup>1</sup>ACTIV-2 SNG001, 2022 (NCT04518410); CoV-Early (Gharbharan), 2022 (NCT04589949); TOGETHER interferon lambda, 2022 (NCT04727424); BLAZE-1 phase 3 (combo), 2021 (NCT04427501); COMET-ICE, 2021 (NCT04545060); CONV-ERT, 2021 (NCT04621123); Cov-2069 (Cohort B : positive SARS-CoV-2 RT-qPCR test result), 2021 (NCT04452318); CT-P59 3.2 part 1, 2021 (NCT04602000); CT-P59 3.2 part 2, 2021 (NCT04602000); Feld, 2021 (NCT04354259); OPTIMISE-C19 (bamlanivimab-etesevimab vs casirivimab-imdevimab), 2021 (NCT04790786); BLAZE-1 phase 2 (combination with etesevimab), 2020 (NCT04427501); BLAZE-1 phase 2 (monotherapy), 2020 (NCT04427501); C3PO, 2020 (NCT04355767); Cov-2067 Weinreich (1200mg) Cohort 1, 2020 (NCT04425629); ACTIV-2 (BRIL-196 and BRIL-198), 0 (NCT04518410); BLAZE 4 LY-CoV1404, 0 (NCT04634409); BLAZE-4, 0 (NCT04634409); TACKLE, 0 (NCT04723394); Bariola, 2021 ()

<sup>2</sup>COLCORONA, 2021 (NCT04322682); PRINCIPLE (COLCHICINE), 2021 (ISRCTN86534580)

<sup>3</sup>Clemency, 2021 (NCT04377711); Ezer N (CONTAIN), 2021 (NCT04435795)

<sup>4</sup>PRINCIPLE, 2021 (ISRCTN86534580); STOIC, 2021 (NCT04416399)